Skip to content
PeptideAgent

Clinics in North Dakota

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What North Dakota law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and verified listings.

North Dakota at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async unclear
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified clinics serving North Dakota

No verified clinics serving North Dakota are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Peptide access rules in North Dakota

Yes. A North Dakota resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a North Dakota-licensed prescriber, including by telemedicine under NDCC 43-17-44, which requires a bona fide relationship, identity verification, and the same standard of care as in-person practice. A compounded peptide is available when it is eligible under federal 503A rules and dispensed by a pharmacy holding a North Dakota State Board of Pharmacy permit. North Dakota is unusual in two ways: every out-of-state pharmacy shipping prescriptions into the state must hold a full North Dakota pharmacy permit, and in-state pharmacies must be majority owned by pharmacists under NDCC 43-15-35. [1] [2] [3] [4] [5] [6] [8]

Compounded GLP-1 access in North Dakota

Because North Dakota requires a full pharmacy permit for every out-of-state shipper, fewer national telehealth pharmacies serve the state, and patients should confirm the pharmacy's North Dakota permit before ordering. [4] [9]

Research use only sellers in North Dakota

The North Dakota Food, Drug, and Cosmetic Act (NDCC chapter 19-02.1) prohibits selling adulterated or misbranded drugs, and NDCC chapter 43-15 limits dispensing of prescription drugs to permitted pharmacies and licensed practitioners. [6] [7] [10]

North Dakota notes on specific peptides

  • Semaglutide: Available branded by prescription, including by telemedicine from a North Dakota-licensed prescriber who has established a bona fide relationship under NDCC 43-17-44. Compounded semaglutide is limited to the federal patient specific exception since April 22, 2025. [2] [9]

How to check a clinic in North Dakota

  1. Confirm the prescribing clinician's license with the North Dakota medical or nursing board.
  2. Ask which pharmacy compounds or dispenses the peptide and check it in the North Dakota State Board of Pharmacy license lookup. [1] [4] [5] [6] [8]
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in North Dakota. [6] [7] [10]

Common questions in North Dakota

Can I get a GLP-1 prescription in North Dakota through telemedicine?

Yes, from a North Dakota-licensed prescriber who establishes a bona fide relationship, verifies your identity, and meets the in-person standard of care under NDCC 43-17-44. Semaglutide and tirzepatide are not controlled substances. [2]

All peptide legal questions for North Dakota

Sources

  1. [1]North Dakota State Board of Pharmacy
  2. [2]NDCC 43-17-44, Telemedicine (in chapter 43-17, Physicians and physician assistants)
  3. [3]NDAC chapter 50-02-15, Telemedicine (North Dakota Board of Medicine)
  4. [4]NDAC chapter 61-08-01, Requirements for out-of-state pharmacies
  5. [5]NDAC chapter 61-02-01, Pharmacy permits (section 61-02-01-03, pharmaceutical compounding standards)
  6. [6]NDCC chapter 43-15, Pharmacy (including 43-15-35, pharmacist ownership)
  7. [7]NDCC chapter 19-02.1, Food, Drug, and Cosmetic Act
  8. [8]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  9. [9]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  10. [10]21 U.S.C. 331, Prohibited acts